JP2018512170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512170A5 JP2018512170A5 JP2018501142A JP2018501142A JP2018512170A5 JP 2018512170 A5 JP2018512170 A5 JP 2018512170A5 JP 2018501142 A JP2018501142 A JP 2018501142A JP 2018501142 A JP2018501142 A JP 2018501142A JP 2018512170 A5 JP2018512170 A5 JP 2018512170A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 193
- 238000000034 method Methods 0.000 claims 26
- 210000004027 cell Anatomy 0.000 claims 20
- 241000124008 Mammalia Species 0.000 claims 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 5
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 3
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 3
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 3
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 3
- 108010012236 Chemokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 3
- 101150063370 Gzmb gene Proteins 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 3
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 3
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 3
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 3
- 102000000588 Interleukin-2 Human genes 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 229940022399 cancer vaccine Drugs 0.000 claims 3
- 238000009566 cancer vaccine Methods 0.000 claims 3
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 238000003364 immunohistochemistry Methods 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 210000003289 regulatory T cell Anatomy 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 2
- 101100179076 Rattus norvegicus Icos gene Proteins 0.000 claims 2
- 102000043396 human ICOS Human genes 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108010041986 DNA Vaccines Proteins 0.000 claims 1
- 229940021995 DNA vaccine Drugs 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 101100179075 Mus musculus Icos gene Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 229940030325 tumor cell vaccine Drugs 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021148509A JP2022002520A (ja) | 2015-03-23 | 2021-09-13 | Ｉｃｏｓに対する抗体 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562137034P | 2015-03-23 | 2015-03-23 | |
| US62/137,034 | 2015-03-23 | ||
| US201562147484P | 2015-04-14 | 2015-04-14 | |
| US62/147,484 | 2015-04-14 | ||
| US201562156588P | 2015-05-04 | 2015-05-04 | |
| US62/156,588 | 2015-05-04 | ||
| US201562242489P | 2015-10-16 | 2015-10-16 | |
| US62/242,489 | 2015-10-16 | ||
| US201562255635P | 2015-11-16 | 2015-11-16 | |
| US62/255,635 | 2015-11-16 | ||
| PCT/US2016/023524 WO2016154177A2 (en) | 2015-03-23 | 2016-03-22 | Antibodies to icos |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148509A Division JP2022002520A (ja) | 2015-03-23 | 2021-09-13 | Ｉｃｏｓに対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512170A JP2018512170A (ja) | 2018-05-17 |
| JP2018512170A5 true JP2018512170A5 (enExample) | 2019-04-25 |
| JP6944924B2 JP6944924B2 (ja) | 2021-10-06 |
Family
ID=56978549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501142A Active JP6944924B2 (ja) | 2015-03-23 | 2016-03-22 | Ｉｃｏｓに対する抗体 |
| JP2021148509A Pending JP2022002520A (ja) | 2015-03-23 | 2021-09-13 | Ｉｃｏｓに対する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148509A Pending JP2022002520A (ja) | 2015-03-23 | 2021-09-13 | Ｉｃｏｓに対する抗体 |
Country Status (34)
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2482849B1 (en) | 2009-09-30 | 2018-06-06 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| US9376493B2 (en) | 2011-03-31 | 2016-06-28 | INSERM (Institut National de la Sante et de la Recherche Mediacale) | Antibodies directed against ICOS and uses thereof |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| JP6647315B2 (ja) | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| KR20170129902A (ko) * | 2015-03-23 | 2017-11-27 | 조운스 테라퓨틱스, 인크. | Icos에 대한 항체 |
| US11149087B2 (en) * | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| KR20180066236A (ko) | 2015-10-22 | 2018-06-18 | 조운스 테라퓨틱스, 인크. | Icos 발현을 계측하기 위한 유전자 특질 |
| ES2781474T3 (es) | 2016-04-07 | 2020-09-02 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas útiles como moduladores de proteínas |
| PE20181884A1 (es) | 2016-04-07 | 2018-12-07 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas utiles como moduladores de proteinas |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| EP3497128A2 (en) | 2016-08-09 | 2019-06-19 | Kymab Limited | Anti-icos antibodies |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| WO2018115859A1 (en) * | 2016-12-20 | 2018-06-28 | Kymab Limited | Multispecific antibody with combination therapy for immuno-oncology |
| JP7290568B2 (ja) * | 2016-12-20 | 2023-06-13 | カイマブ・リミテッド | 癌免疫療法のための併用療法での多重特異性抗体 |
| US20200062735A1 (en) | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| WO2018187191A1 (en) * | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
| TWI788340B (zh) * | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| WO2018225034A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| CA3066048A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| EP3635011A1 (en) | 2017-06-09 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| US11299540B2 (en) | 2017-06-18 | 2022-04-12 | Kindred Biosciences, Inc. | IL17A antibodies and antagonists for veterinary use |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| US20200129482A1 (en) * | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
| GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| CN111295394B (zh) * | 2017-08-11 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 抗cd8抗体及其用途 |
| JP2020531002A (ja) | 2017-08-15 | 2020-11-05 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学用ｉｇｇ ｆｃ変異体 |
| WO2019053613A2 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | POLY THERAPY FOR THE TREATMENT OF CANCER |
| DK3684949T3 (en) | 2017-09-22 | 2024-07-08 | Univ Washington | In situ combinatorial labeling of cellular molecules |
| CN111417630B (zh) | 2017-10-05 | 2023-06-06 | 葛兰素史克知识产权开发有限公司 | 干扰素基因刺激因子(sting)的调节剂 |
| EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| JP7391868B2 (ja) | 2017-12-22 | 2023-12-05 | ジョウンセ セラピューティクス， インク． | Ｌｉｌｒｂ２に対する抗体 |
| TW202000891A (zh) | 2018-03-07 | 2020-01-01 | 英商葛蘭素史克智慧財產發展有限公司 | 純化抗體之方法 |
| BR112020018539A2 (pt) | 2018-03-23 | 2020-12-29 | Bristol-Myers Squibb Company | Anticorpos contra mica e/ou micb e usos dos mesmos |
| EP3793598A1 (en) * | 2018-05-14 | 2021-03-24 | Jounce Therapeutics, Inc. | Methods of treating cancer |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| CN112469441A (zh) | 2018-05-31 | 2021-03-09 | 葛兰素史克知识产权开发有限公司 | 用icos结合蛋白和精氨酸甲基转移酶抑制剂的组合疗法 |
| CN112469416A (zh) | 2018-05-31 | 2021-03-09 | 葛兰素史克知识产权开发有限公司 | 用于治疗癌症的ii型蛋白质精氨酸甲基转移酶抑制剂和icos结合蛋白的组合 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| WO2020081905A1 (en) | 2018-10-18 | 2020-04-23 | Jounce Therapeutics, Inc | Methods for treating cancer |
| CA3117746A1 (en) | 2018-10-22 | 2020-04-30 | Glaxosmithkline Intellectual Property Development Limited | Dosing |
| US20210380942A1 (en) | 2018-10-24 | 2021-12-09 | Jounce Therapeutics, Inc. | Methods and compositions for the treatment of cancer and infectious diseases |
| US20210355222A1 (en) | 2018-10-26 | 2021-11-18 | Jounce Therapeutics, Inc. | Methods of Treating Cancer |
| US20220135682A1 (en) * | 2019-03-11 | 2022-05-05 | Jounce Therapeutics, Inc. | Anti-ICOS Antibodies for the Treatment of Cancer |
| CN114391015A (zh) | 2019-05-16 | 2022-04-22 | 斯汀塞拉股份有限公司 | 苯并[b][1,8]萘啶乙酸衍生物和使用方法 |
| CN114302875A (zh) | 2019-05-16 | 2022-04-08 | 斯汀塞拉股份有限公司 | 氧代吖啶基乙酸衍生物及使用方法 |
| CN114174537A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 细胞定位特征和组合疗法 |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| US11878009B2 (en) | 2019-09-10 | 2024-01-23 | Great Novel Therapeutics Biotech & Medicals Corporation | Anticancer combination of chidamide and celecoxib salts |
| WO2021056025A2 (en) * | 2019-09-20 | 2021-03-25 | Board Of Regents, The University Of Texas System | Anti-epha10 antibodies and methods of use thereof |
| US20220378909A1 (en) | 2019-11-05 | 2022-12-01 | Jounce Therapeutics, Inc. | Methods of Treating Cancer with Anti-PD-1 Antibodies |
| CN114981265B (zh) | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| US11396647B2 (en) | 2020-01-07 | 2022-07-26 | Board Of Regents, The University Of Texas System | Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy |
| EP4090771A1 (en) | 2020-01-13 | 2022-11-23 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
| CN115362270A (zh) | 2020-01-29 | 2022-11-18 | 得克萨斯州大学系统董事会 | Egfr/her2酪氨酸激酶抑制剂和/或her2/her3抗体在具有nrg1融合的癌症的治疗中的用途 |
| EP4096789A4 (en) | 2020-01-29 | 2023-10-11 | Board of Regents, The University of Texas System | USE OF POZIOTINIB TO TREAT CANCER WITH NRG1 FUSIONS |
| CA3171557A1 (en) | 2020-04-14 | 2021-10-21 | Marc S. BALLAS | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies |
| AU2021257570A1 (en) | 2020-04-14 | 2022-11-03 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| AU2021256925A1 (en) | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
| WO2021216417A1 (en) | 2020-04-20 | 2021-10-28 | Jounce Therapeutics, Inc. | Compositions and methods for vaccination and the treatment of infectious diseases |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| IL300916A (en) | 2020-08-31 | 2023-04-01 | Bristol Myers Squibb Co | Cell localization signature and immunotherapy |
| WO2022081841A1 (en) * | 2020-10-16 | 2022-04-21 | Fred Hutchinson Cancer Research Center | Specific targeting of tumor-infiltrating regulatory t cells (tregs) using icos and il-1r1 |
| EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022146947A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| MX2023007650A (es) | 2020-12-28 | 2023-09-11 | Bristol Myers Squibb Co | Metodos de tratamiento de tumores. |
| AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| CA3219336A1 (en) * | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| WO2023056361A1 (en) | 2021-09-29 | 2023-04-06 | Board Of Regents, The University Of Texas System | Anti-hsp70 antibodies and therapeutic uses thereof |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| PE20251671A1 (es) | 2022-03-15 | 2025-06-30 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
| EP4531916A1 (en) | 2022-06-02 | 2025-04-09 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| CN121712571A (zh) | 2023-08-15 | 2026-03-20 | 百时美施贵宝公司 | 陶瓷羟基磷灰石色谱流通法 |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| JP4463418B2 (ja) | 1997-09-23 | 2010-05-19 | ドイツ連邦共和国 | Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用 |
| DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| JP5341287B2 (ja) | 1998-12-03 | 2013-11-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｃｔｌａ−４遮断薬を用いる自己抗原に対するｔ細胞の刺激 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2000046240A2 (en) | 1999-02-03 | 2000-08-10 | Amgen Inc. | Polypeptides involved in immune response |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1218504B1 (en) | 1999-09-21 | 2007-07-11 | Genetics Institute, LLC | Gl50 molecules and uses therefor |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| WO2001044463A1 (en) | 1999-12-15 | 2001-06-21 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| JP3597140B2 (ja) * | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| AU7309601A (en) | 2000-06-28 | 2002-01-08 | Genetics Inst | Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス，インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
| US20030124149A1 (en) | 2001-07-06 | 2003-07-03 | Shalaby Shalaby W. | Bioactive absorbable microparticles as therapeutic vaccines |
| RU2321630C2 (ru) | 2001-08-03 | 2008-04-10 | Гликарт Биотекнолоджи АГ | Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью |
| US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
| EP1441758A2 (de) | 2001-11-09 | 2004-08-04 | MediGene Aktiengesellschaft | Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| JP4628679B2 (ja) | 2002-04-09 | 2011-02-09 | 協和発酵キリン株式会社 | Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞 |
| WO2003084569A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Drug containing antibody composition |
| JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2347241T3 (es) | 2002-12-16 | 2010-10-27 | Genentech, Inc. | Variantes de inmunoglobulina y sus utilizaciones. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
| CN101979650B (zh) | 2003-10-22 | 2015-09-16 | 凯克研究生院 | 使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法 |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| EP1740617B1 (en) | 2004-04-23 | 2013-10-16 | BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten | Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo |
| WO2006004716A2 (en) | 2004-06-29 | 2006-01-12 | The Johns Hopkins University | Amelioration of drug-induced toxicity |
| CA2589895A1 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| JP2006265155A (ja) | 2005-03-23 | 2006-10-05 | Link Genomics Kk | 癌の免疫療法 |
| CN104436190A (zh) | 2005-06-08 | 2015-03-25 | 达纳-法伯癌症研究院公司 | 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物 |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN101679966B (zh) | 2007-01-24 | 2014-03-12 | 协和发酵麒麟株式会社 | 具有增强的效应子活性的遗传重组抗体组合物 |
| JP5575636B2 (ja) * | 2007-05-07 | 2014-08-20 | メディミューン，エルエルシー | 抗ｉｃｏｓ抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用 |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| US8840889B2 (en) * | 2009-08-13 | 2014-09-23 | The Johns Hopkins University | Methods of modulating immune function |
| EP2482849B1 (en) | 2009-09-30 | 2018-06-06 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| CN102753195A (zh) | 2009-12-07 | 2012-10-24 | 小利兰·斯坦福大学托管委员会 | 用于增强抗肿瘤抗体疗法的方法 |
| WO2011097477A1 (en) * | 2010-02-04 | 2011-08-11 | The Trustees Of The University Of Pennsylvania | Icos critically regulates the expansion and function of inflammatory human th17 cells |
| US9410205B2 (en) | 2010-02-18 | 2016-08-09 | New York University | Methods for predicting survival in metastatic melanoma patients |
| CA2826649C (en) * | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| US9376493B2 (en) | 2011-03-31 | 2016-06-28 | INSERM (Institut National de la Sante et de la Recherche Mediacale) | Antibodies directed against ICOS and uses thereof |
| DK2872646T3 (en) | 2012-07-12 | 2017-12-04 | Université Paris Descartes | PROCEDURES FOR PREDICTING SURVIVAL TIME AND TREATMENT RESPONSE OF A PATIENT, SUFFERING A FAST CANCER WITH A SIGNATURE OF AT LEAST 7 GENES |
| EP2911669B1 (en) | 2012-10-26 | 2024-04-10 | The University of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| MA38483A1 (fr) | 2013-03-15 | 2018-02-28 | Bristol Myers Squibb Co | Inhibiteurs de l'ido |
| KR20250091304A (ko) | 2013-03-15 | 2025-06-20 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| MA41414A (fr) * | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| KR20170129902A (ko) * | 2015-03-23 | 2017-11-27 | 조운스 테라퓨틱스, 인크. | Icos에 대한 항체 |
| KR20180066236A (ko) * | 2015-10-22 | 2018-06-18 | 조운스 테라퓨틱스, 인크. | Icos 발현을 계측하기 위한 유전자 특질 |
| JP2019517557A (ja) * | 2016-06-10 | 2019-06-24 | アイオー セラピューティクス インコーポレイテッド | 癌免疫療法のための受容体選択的レチノイドおよびレキシノイド化合物および免疫調節因子 |
| US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
-
2016
- 2016-03-22 KR KR1020177030281A patent/KR20170129902A/ko not_active Abandoned
- 2016-03-22 HU HUE16769535A patent/HUE049938T2/hu unknown
- 2016-03-22 MX MX2017012129A patent/MX386500B/es unknown
- 2016-03-22 AU AU2016235362A patent/AU2016235362B2/en not_active Ceased
- 2016-03-22 SG SG10202001019TA patent/SG10202001019TA/en unknown
- 2016-03-22 MA MA053297A patent/MA53297A/fr unknown
- 2016-03-22 CN CN201680026223.2A patent/CN107530428B/zh not_active Expired - Fee Related
- 2016-03-22 MD MDE20180112T patent/MD3273992T2/ro not_active IP Right Cessation
- 2016-03-22 CN CN202210469652.4A patent/CN114907481A/zh active Pending
- 2016-03-22 EA EA201792078A patent/EA037621B1/ru unknown
- 2016-03-22 BR BR112017020054A patent/BR112017020054A2/pt not_active Application Discontinuation
- 2016-03-22 CA CA2978185A patent/CA2978185A1/en active Pending
- 2016-03-22 JP JP2018501142A patent/JP6944924B2/ja active Active
- 2016-03-22 PT PT167695352T patent/PT3273992T/pt unknown
- 2016-03-22 US US15/076,867 patent/US10023635B2/en active Active
- 2016-03-22 TW TW105108884A patent/TWI719970B/zh not_active IP Right Cessation
- 2016-03-22 SI SI201630870T patent/SI3273992T1/sl unknown
- 2016-03-22 ME MEP-2020-166A patent/ME03819B/me unknown
- 2016-03-22 EP EP20167918.0A patent/EP3735986A1/en not_active Withdrawn
- 2016-03-22 PH PH1/2017/501748A patent/PH12017501748B1/en unknown
- 2016-03-22 SG SG11201707769VA patent/SG11201707769VA/en unknown
- 2016-03-22 RS RS20200941A patent/RS60614B1/sr unknown
- 2016-03-22 SM SM20200444T patent/SMT202000444T1/it unknown
- 2016-03-22 PH PH1/2021/552158A patent/PH12021552158A1/en unknown
- 2016-03-22 DK DK16769535.2T patent/DK3273992T3/da active
- 2016-03-22 PL PL16769535T patent/PL3273992T3/pl unknown
- 2016-03-22 KR KR1020237040603A patent/KR20230164243A/ko not_active Ceased
- 2016-03-22 LT LTEP16769535.2T patent/LT3273992T/lt unknown
- 2016-03-22 RU RU2017137020A patent/RU2742241C2/ru active
- 2016-03-22 HR HRP20201090TT patent/HRP20201090T1/hr unknown
- 2016-03-22 WO PCT/US2016/023524 patent/WO2016154177A2/en not_active Ceased
- 2016-03-22 EP EP16769535.2A patent/EP3273992B1/en active Active
- 2016-03-22 ES ES16769535T patent/ES2811345T3/es active Active
-
2017
- 2017-08-31 ZA ZA201705920A patent/ZA201705920B/en unknown
- 2017-09-05 IL IL254338A patent/IL254338B/en unknown
- 2017-09-22 CL CL2017002401A patent/CL2017002401A1/es unknown
- 2017-09-25 MX MX2021011667A patent/MX2021011667A/es unknown
- 2017-10-18 CO CONC2017/0010618A patent/CO2017010618A2/es unknown
- 2017-10-23 EC ECIEPI201770399A patent/ECSP17070399A/es unknown
-
2018
- 2018-06-20 US US16/012,867 patent/US10570203B2/en active Active
-
2020
- 2020-08-12 CY CY20201100755T patent/CY1123409T1/el unknown
- 2020-09-16 US US17/022,856 patent/US20210171635A1/en not_active Abandoned
-
2021
- 2021-09-13 JP JP2021148509A patent/JP2022002520A/ja active Pending
- 2021-09-29 IL IL286807A patent/IL286807A/en unknown
-
2022
- 2022-03-01 AU AU2022201408A patent/AU2022201408A1/en not_active Abandoned